Skip to main content
Top
Published in: Endocrine Pathology 1/2018

01-03-2018

Long Non-coding RNA Linc-ROR Is Upregulated in Papillary Thyroid Carcinoma

Authors: Ranran Zhang, Heather Hardin, Wei Huang, Darya Buehler, Ricardo V. Lloyd

Published in: Endocrine Pathology | Issue 1/2018

Login to get access

Abstract

Long non-coding RNAs (lncRNAs) may contribute to carcinogenesis and tumor progression by regulating transcription and gene expression. The role of lncRNAs in the regulation of thyroid cancer progression is being extensively examined. Here, we analyzed three lncRNAs that were overexpressed in papillary thyroid carcinomas, long intergenic non-protein coding RNA, regulator of reprogramming (Linc-ROR, ROR) PVT1 oncogene (PVT1), and HOX transcript antisense intergenic RNA (HOTAIR) to determine their roles in thyroid tumor development and progression. ROR expression has not been previously examined in thyroid carcinomas. Tissue microarrays (TMAs) of formalin-fixed paraffin-embedded tissue sections from 129 thyroid cases of benign and malignant tissues were analyzed by in situ hybridization (ISH), automated image analysis, and real-time PCR. All three lncRNAs were most highly expressed in the nuclei of PTCs. SiRNA experiments with a PTC cell line, TPC1, showed inhibition of proliferation with siRNAs for all three lncRNAs while invasion was inhibited with siRNAs for ROR and HOTAIR. SiRNA experiments with ROR also led to increased expression of miR-145, supporting the role of ROR as an endogenous miR-145 sponge. After treatment with TGF-β, there was increased expression of ROR, PVT1, and HOTAIR in the PTC1 cell line compared to control groups, indicating an induction of their expression during epithelial to mesenchymal transition (EMT). These results indicate that ROR, PVT1, and HOTAIR have important regulatory roles during the development of PTCs.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lloyd RV, Osamura RY, Kloppel G, Rosai J. WHO Classification of Tumours of Endocrine Organs, 4th Edition, International Agency for Research on Cancer (IARC) Lyon, France, 2017. Lloyd RV, Osamura RY, Kloppel G, Rosai J. WHO Classification of Tumours of Endocrine Organs, 4th Edition, International Agency for Research on Cancer (IARC) Lyon, France, 2017.
2.
go back to reference Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7(10):569–580.CrossRefPubMed Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7(10):569–580.CrossRefPubMed
3.
go back to reference Livoisi VA. Papillary thyroid carcinoma: An update. Mod Pathol. 2011;24(Suppl 2):S1–S9.CrossRef Livoisi VA. Papillary thyroid carcinoma: An update. Mod Pathol. 2011;24(Suppl 2):S1–S9.CrossRef
4.
go back to reference Li X, Wu Z, Fu X, Han W. Long noncoding RNAs: Insights from biological features and functions to diseases. Med Res Rev. 2013;33(3):517–553.CrossRefPubMed Li X, Wu Z, Fu X, Han W. Long noncoding RNAs: Insights from biological features and functions to diseases. Med Res Rev. 2013;33(3):517–553.CrossRefPubMed
5.
go back to reference Zhang R, Hardin H, Chen J, Guo Z, Lloyd RV. Non-coding RNAs in Thyroid Cancer Endocr Pathol. 2016;27:12–20.CrossRefPubMed Zhang R, Hardin H, Chen J, Guo Z, Lloyd RV. Non-coding RNAs in Thyroid Cancer Endocr Pathol. 2016;27:12–20.CrossRefPubMed
7.
go back to reference He H, Nagy R, Liyanarachchi S, Jiao H, Li W, Suster S, Kere J, de la Chapelle A. A susceptibility locus for papillary thyroid carcinoma on chormosome 8q24. Cancer Res. 2009;69(2):625–631.CrossRefPubMedPubMedCentral He H, Nagy R, Liyanarachchi S, Jiao H, Li W, Suster S, Kere J, de la Chapelle A. A susceptibility locus for papillary thyroid carcinoma on chormosome 8q24. Cancer Res. 2009;69(2):625–631.CrossRefPubMedPubMedCentral
8.
go back to reference He H, Li W, Liyanarachchi S, Jendrzejewski J, Srinivas M, Davuluri RV, Nagy R, de la Chapelle A. Genetic predisposition to papillary thryoid carcinoma: Involvement of FOXE1, TSHR, and a Novel lincRNA Gene, PTCSC2. J Clin Endocrinol Metab. 2015;100(1):E164–E172.CrossRefPubMed He H, Li W, Liyanarachchi S, Jendrzejewski J, Srinivas M, Davuluri RV, Nagy R, de la Chapelle A. Genetic predisposition to papillary thryoid carcinoma: Involvement of FOXE1, TSHR, and a Novel lincRNA Gene, PTCSC2. J Clin Endocrinol Metab. 2015;100(1):E164–E172.CrossRefPubMed
9.
go back to reference Jendrzejewski J, He H, Randomska HS, Li W, Tomsic J, Liyanarachchi S, Davuluri RV, Nagy R, de la Chapelle A. The polymorphism rs944289 predisposes to papillary thryoid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type. Proc Natl Acad Sci USA. 2012;109(22):8646–8651.CrossRefPubMedPubMedCentral Jendrzejewski J, He H, Randomska HS, Li W, Tomsic J, Liyanarachchi S, Davuluri RV, Nagy R, de la Chapelle A. The polymorphism rs944289 predisposes to papillary thryoid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type. Proc Natl Acad Sci USA. 2012;109(22):8646–8651.CrossRefPubMedPubMedCentral
10.
go back to reference Zhang R, Hardin H, Huang W, Chen J, Asioli S, Righi A, Maletta F, Sapino A, Lloyd RV. MALAT1 Long non-coding RNA expression in thyroid tissues: Analysis by in situ hybridizastion and real-time PCR. Endocr Pathology 2017;28:7–12.CrossRef Zhang R, Hardin H, Huang W, Chen J, Asioli S, Righi A, Maletta F, Sapino A, Lloyd RV. MALAT1 Long non-coding RNA expression in thyroid tissues: Analysis by in situ hybridizastion and real-time PCR. Endocr Pathology 2017;28:7–12.CrossRef
11.
go back to reference Buehler D, Hardin H, Shan W, Montemayor-Garcia C, Rush PS, Asioli S, Chen H, Lloyd RV. Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas. Mod Pathol. 2012;26(10):54–61.PubMedPubMedCentral Buehler D, Hardin H, Shan W, Montemayor-Garcia C, Rush PS, Asioli S, Chen H, Lloyd RV. Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas. Mod Pathol. 2012;26(10):54–61.PubMedPubMedCentral
12.
go back to reference Guo Z, Hardin H, Montemayor-Garcia C, Asioli S, Righi A, Maletta F, Sapino A, Llloyd RV. In situ hybridization analysis of miR-146b-5p and miR-21 in thyroid nodules: Diagnostic implications. Endocr Pathol. 2015;26(2):157–163. Guo Z, Hardin H, Montemayor-Garcia C, Asioli S, Righi A, Maletta F, Sapino A, Llloyd RV. In situ hybridization analysis of miR-146b-5p and miR-21 in thyroid nodules: Diagnostic implications. Endocr Pathol. 2015;26(2):157–163.
13.
go back to reference Huang W, Eickhoff JC, Mehraein-Ghomi F, Church DR, Wilding G, Basu HS. Expression of spermidine/spermine N1-acetyl transferase (SSAT) in human prostate tissues is related to prostate cancer progression and metastasis. Prostate. 2015;75(11):1150–1159.CrossRefPubMedPubMedCentral Huang W, Eickhoff JC, Mehraein-Ghomi F, Church DR, Wilding G, Basu HS. Expression of spermidine/spermine N1-acetyl transferase (SSAT) in human prostate tissues is related to prostate cancer progression and metastasis. Prostate. 2015;75(11):1150–1159.CrossRefPubMedPubMedCentral
14.
go back to reference Hardin H, Guo Z, Shan W, Montemayor-Garcia C, Asioli S, Yu XM, Harrison AD, Chen H, Lloyd RV. The roles of the epithelial-mesenchymal transition marker PRRX1 and miR-146b-5p in papillary thyroid carcinoma progression. Am J Pathol. 2014;184(8):2342–2354.CrossRefPubMedPubMedCentral Hardin H, Guo Z, Shan W, Montemayor-Garcia C, Asioli S, Yu XM, Harrison AD, Chen H, Lloyd RV. The roles of the epithelial-mesenchymal transition marker PRRX1 and miR-146b-5p in papillary thyroid carcinoma progression. Am J Pathol. 2014;184(8):2342–2354.CrossRefPubMedPubMedCentral
15.
go back to reference Hardin H, Yu X-M, Harrison AD, Larrain C, Zhang R, Chen J, Chen H, Lloyd RV. Generation of novel thyroid cancer stem-like cell clones effects of resveratrol and valproic acid. Am J Pathol. 2016;186(6):1662–1673.CrossRefPubMed Hardin H, Yu X-M, Harrison AD, Larrain C, Zhang R, Chen J, Chen H, Lloyd RV. Generation of novel thyroid cancer stem-like cell clones effects of resveratrol and valproic acid. Am J Pathol. 2016;186(6):1662–1673.CrossRefPubMed
17.
go back to reference Di W, LiQ, Shen W, Guo H, Zhao S. The long non-coding RNA HOTAIR promotes thyroid cancer cell growth, invasion and migration through the miR-1-CCND2 axis. Am J Cancer Res. 2017;7:1298–1309.PubMedPubMedCentral Di W, LiQ, Shen W, Guo H, Zhao S. The long non-coding RNA HOTAIR promotes thyroid cancer cell growth, invasion and migration through the miR-1-CCND2 axis. Am J Cancer Res. 2017;7:1298–1309.PubMedPubMedCentral
18.
21.
go back to reference Pan Y, Li C, Chen J, Zhang K, Chu X, Wang R, Chen L. The emerging roles of long noncoding RNA ROR (lincRNA-ROR) and its possible mechanisms in human cancers. Cell Physiol Biochem. 2016;40:219–229.CrossRefPubMed Pan Y, Li C, Chen J, Zhang K, Chu X, Wang R, Chen L. The emerging roles of long noncoding RNA ROR (lincRNA-ROR) and its possible mechanisms in human cancers. Cell Physiol Biochem. 2016;40:219–229.CrossRefPubMed
22.
go back to reference Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipotsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–715.CrossRefPubMedPubMedCentral Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipotsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–715.CrossRefPubMedPubMedCentral
24.
go back to reference Cancer Genome Atlas Research Network. Integrated genomic characterizatin of papillary thyroid carcinoma. Cell. 2014;159(3):676–690.CrossRef Cancer Genome Atlas Research Network. Integrated genomic characterizatin of papillary thyroid carcinoma. Cell. 2014;159(3):676–690.CrossRef
25.
go back to reference Liu J, Singh B, Tallini G, Carlson DL, Katabi N, Shaha A, Tuttle RM, Ghossein RA. Follicular variant of papillary thyroid carcinoma: A clinicopathologtic study of a problematic entity. Cancer. 2006;107:1253–1264.CrossRef Liu J, Singh B, Tallini G, Carlson DL, Katabi N, Shaha A, Tuttle RM, Ghossein RA. Follicular variant of papillary thyroid carcinoma: A clinicopathologtic study of a problematic entity. Cancer. 2006;107:1253–1264.CrossRef
26.
go back to reference Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo FR, Thompson LD, Barletta JA, Wenig BM, Al Ghuzlan A, Kakudo K, Giordano TJ, Alves VA, Khanafshar E, Asa SL, El-Naggar AK, Gooding WE, Hodak SP, Lloyd RV, Maytal G, Mete O, Nikiforova MN, Nose V, Papotti M, Poller DN, Sadow PM, Tischler AS, Tuttle AS, Wall KB, LiVolsi VA, Randolph GW, Ghossein RA. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: A paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2016;2:1023–1029.CrossRefPubMedPubMedCentral Nikiforov YE, Seethala RR, Tallini G, Baloch ZW, Basolo FR, Thompson LD, Barletta JA, Wenig BM, Al Ghuzlan A, Kakudo K, Giordano TJ, Alves VA, Khanafshar E, Asa SL, El-Naggar AK, Gooding WE, Hodak SP, Lloyd RV, Maytal G, Mete O, Nikiforova MN, Nose V, Papotti M, Poller DN, Sadow PM, Tischler AS, Tuttle AS, Wall KB, LiVolsi VA, Randolph GW, Ghossein RA. Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: A paradigm shift to reduce overtreatment of indolent tumors. JAMA Oncol. 2016;2:1023–1029.CrossRefPubMedPubMedCentral
27.
go back to reference Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X. Evidence that one subset of anaplastic thryoid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer. 2005;103:2261–2268.CrossRefPubMed Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X. Evidence that one subset of anaplastic thryoid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer. 2005;103:2261–2268.CrossRefPubMed
28.
go back to reference Hardin H, Montemayor-Garcia C, Lloyd RV. Thyroid cancer stem-like cells and epithelial-mesenchymal transition in thyroid cancers. Hum Pathol. 2013;44:1707–1713.CrossRefPubMed Hardin H, Montemayor-Garcia C, Lloyd RV. Thyroid cancer stem-like cells and epithelial-mesenchymal transition in thyroid cancers. Hum Pathol. 2013;44:1707–1713.CrossRefPubMed
29.
go back to reference Zane M, Scavo E, Catalano V, Bonanno M, Todaro M, De Maria R, Stassi G. Normal vs cancer thyroid stem cells: The road to transformation. Oncogene. 2016;35:805–815.CrossRefPubMed Zane M, Scavo E, Catalano V, Bonanno M, Todaro M, De Maria R, Stassi G. Normal vs cancer thyroid stem cells: The road to transformation. Oncogene. 2016;35:805–815.CrossRefPubMed
30.
go back to reference Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, Dogan S, Ricarte-Filho JC, Krishnamoorthy GP, Xu B, Schultz N, Berger MF, Sander C, Taylor BS, Ghossein R, Ganly I, Fagin JA. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thryoid cancers. J Clin Invest. 2016;126(3):1052–1066.CrossRefPubMedPubMedCentral Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, Dogan S, Ricarte-Filho JC, Krishnamoorthy GP, Xu B, Schultz N, Berger MF, Sander C, Taylor BS, Ghossein R, Ganly I, Fagin JA. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thryoid cancers. J Clin Invest. 2016;126(3):1052–1066.CrossRefPubMedPubMedCentral
31.
go back to reference Braun J, Hoang-Vu C, Dralle H, Hutelmaier S. Downregulation of microRNAs directs the EMT and invasive potential of anapladstic thyroid carcinomas. Oncogene. 2010;29(29):4237–4244.CrossRefPubMed Braun J, Hoang-Vu C, Dralle H, Hutelmaier S. Downregulation of microRNAs directs the EMT and invasive potential of anapladstic thyroid carcinomas. Oncogene. 2010;29(29):4237–4244.CrossRefPubMed
32.
go back to reference Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, Volinia S, Coluzzi S, Leone V, Borbone E, Liu CG, Petrocca F, Troncone G, Calin GA, Scarpa A, Colato C, Tallini G, Santoro M, Croce CM, Fusco A. Specific microRNAs are downregulated inhuman thyroid anaplastic carcinomas. Oncogene. 2007;26(54):7590–7595.CrossRefPubMed Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, Volinia S, Coluzzi S, Leone V, Borbone E, Liu CG, Petrocca F, Troncone G, Calin GA, Scarpa A, Colato C, Tallini G, Santoro M, Croce CM, Fusco A. Specific microRNAs are downregulated inhuman thyroid anaplastic carcinomas. Oncogene. 2007;26(54):7590–7595.CrossRefPubMed
33.
go back to reference Maqsodi B, Nikoloff C. Non-isotopic method for in situ IncRNA visualization and quantitation. Methods Mol Biol. 2016;1402: 165–176.CrossRefPubMed Maqsodi B, Nikoloff C. Non-isotopic method for in situ IncRNA visualization and quantitation. Methods Mol Biol. 2016;1402: 165–176.CrossRefPubMed
34.
go back to reference Mehra R, Shi Y, Udager AM, Prensner JR, Sahu A, Iyer MK, Siddiqui J, Cao X, Wei J, Jiang H, Feng FY, Chinnaiyan AM. A novel RNA in situ hybridization assay for the long noncoding RNA SChLAP1 predicts poor clinical outcome after radical prostatectomy in clinical outcome after radical Prostatectomy in clinically localized prostate cancer. Neoplasia. 2014;16:1121–1127.CrossRefPubMedPubMedCentral Mehra R, Shi Y, Udager AM, Prensner JR, Sahu A, Iyer MK, Siddiqui J, Cao X, Wei J, Jiang H, Feng FY, Chinnaiyan AM. A novel RNA in situ hybridization assay for the long noncoding RNA SChLAP1 predicts poor clinical outcome after radical prostatectomy in clinical outcome after radical Prostatectomy in clinically localized prostate cancer. Neoplasia. 2014;16:1121–1127.CrossRefPubMedPubMedCentral
Metadata
Title
Long Non-coding RNA Linc-ROR Is Upregulated in Papillary Thyroid Carcinoma
Authors
Ranran Zhang
Heather Hardin
Wei Huang
Darya Buehler
Ricardo V. Lloyd
Publication date
01-03-2018
Publisher
Springer US
Published in
Endocrine Pathology / Issue 1/2018
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-017-9507-2

Other articles of this Issue 1/2018

Endocrine Pathology 1/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine